抗生素
单核细胞增生李斯特菌
微生物学
抗菌剂
氨氯地平
金黄色葡萄球菌
药理学
体内
离体
医学
细菌
生物
内科学
生物技术
遗传学
血压
作者
Kaushiki Mazumdar,K. Asok Kumar,Noton K. Dutta
标识
DOI:10.1016/j.ijantimicag.2010.05.003
摘要
The appearance of multiresistant bacterial strains coupled with the globally ongoing problem of infectious diseases point to the imperative need for novel and affordable antimicrobial drugs. The antibacterial potential of cardiovascular non-antibiotics such as amlodipine (AML), dobutamine, lacidipine, nifedipine and oxyfedrine has been reported previously. Of these drugs, AML proved to have the most significant antibacterial activity against Gram-positive and Gram-negative bacteria. Time-kill curve studies indicate that this Ca(2+) channel blocker exhibits bactericidal activity against Listeria monocytogenes and Staphylococcus aureus. AML could protect against murine listeriosis and salmonellosis at doses ranging within its maximum recommended human or non-toxic ex vivo dose. AML acts as a 'helper compound' in synergistic combination with streptomycin against several Gram-positive and Gram-negative bacterial strains in vitro as well as in the murine salmonellosis model in vivo. The present review focuses on the possible use of cardiovascular non-antibiotics such as AML as auxiliary compound targets for synergistic combinations in infections and hypertension conditions, rationalised on the basis of the activities of the compounds.
科研通智能强力驱动
Strongly Powered by AbleSci AI